Her doctoral research focused on bacteriophage-mediated regulation of bacterial transcription. Elena Forchielli is an Associate within the Planetary Health division of RA Capital Management. While at Acceleron he successfully launched the company's first blockbuster asset - REBLOZYL - and brought in the company's lead drug - Sotatercept - prior to Acceleron's eventual sale to Merck in 2021. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (RA Capital). He was Vice President of Merck business development and licensing where he led BD activities in the US (West Coast), Europe, and Asia Pacific region, as well as President of MRL Ventures where he led equity investing in early-stage therapeutics companies. Asia Pacific +65 6212 1000. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. Largest investment: 7.9 million shares of Vor Biopharma worth $142 million at the time of its IPO . She previously worked as a Finance Associate at the MFA Companies. Emily Greenis a Visual Identity Designer at RA Capital Management. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products. Sonias primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to this role, Erich mapped a number of competitive landscapes including lung cancer, obesity, and chronic kidney disease. Prior to RAVen, Emily worked as Director, Talent Acquisition, at Generation Bio, leading hiring across all functions and building out systems to support that growth. Peter also leads the firms engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. Prior to GHP, Lorena served as an Assurance Senior at EY. Earlier in his career, he was Head of Early Analytical Development for Novartis Cell and Gene Therapies Unit and worked on research teams at the National Cancer Institute with Dr. Steven Rosenberg, the University of Pennsylvania Gene Therapy Program with Dr. Jim Wilson, and Johnson and Johnsons Immunology Discovery group. Pieters primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. Rajeev Shah is a Managing Partner at RA Capital Management. Prior to this, Gerald was Director of Scientific Operations for RA Capital. She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners and Entrepreneurs-In-Residence within RAVen. Ally Boertzel is an Executive Assistant at RA Ventures (RAVen). He also gained extensive legislative and public policy experience early in his career as a Legislative Aide to former United States Senator David Boren, and as a Domestic Policy Advisor to former Vice President Al Gore. Biotech's Dulcius Ex Asperis: The Way Through This Downturn Zach holds a BS in Molecular Biophysics and Biochemistry from Yale University, and a PhD in Neurobiology and Behavior from the University of Washington. From 1997-2000, Scott served as General Manager of Biopharmaceuticals, Corporate Vice President of Business Development, and a member of the Board ofDirectors of Altus Pharmaceuticals, Inc (Nasdaq: ALTU). Peter Kolchinsky's Post - LinkedIn Angela previously held roles as Senior Director of Clinical Operations and Patient Advocacy at Vigil Neuroscience and at Ra Pharmaceuticals. During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the companys first product, and execution of a transformational, multi-billion collaboration. The strange and special case of epinephrine | by Peter Kolchinsky | The Robert received his BS in mechanical engineering from the University of Houston. He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. Bracketts primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Dan studied Network Communications & Information Services at Lincoln Technical. Kriti previously served as Co-Director and Regional Director, South Asia for MIT Hacking Medicine. The Great American Drug Deal examines the healthcare landscape through the lens of this contract, including the government's role in inventing drugs, direct-to-consumer advertising, the opioid crisis, the price-jacking of old drugs, and the impact on America of lower drug costs in other countries. Drew has a BS in Chemical Engineering from University of Virginia and a PhD in Chemical Engineering from Massachusetts Institute of Technology. Kriti holds a B.S. Peter Kolchinsky - Biography - MarketScreener.com Brendan has more than 18 years of experience as a tax professional. After the acquisition, Tim was named President of Genzymes Renal Division and GelTex Pharmaceuticals. Daniel has a BS in Mechanical Engineering from Lehigh University and a MS in Energy Policy & Climate from Johns Hopkins University. Gabe has a BS in Biology from Cornell University and a PhD in Biology from Northeastern University. Erin holds a Bachelor of Fine Arts degree from the Massachusetts College of Art & Design. in Biomedical Anthropology from the University of Pennsylvania. View Profile. Previously, Jake covered solid tumor oncology landscapes. Prior to RA, Gunes served as a scientist within the PCMM Program at Boston Childrens Hospital and her research focused on biophysical characterization of different amyloid fibrils. Michaels primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. As Executive Director of Business Development at Celgene, Emily was responsible for all aspects of deal evaluation, negotiation, and execution for licensing deals, mergers and acquisitions, and collaborations, with a focus on immune-inflammatory and neurodegenerative diseases. from Harvard College and an M.B.A. from Harvard Business School. Mark brings to RAVen more than twenty-five years of leadership experience in the life sciences industryspanning operations, corporate development, legal affairs, and intellectual property. While at Tamarack, he managed coverage expansion into commercial-stage biotech, pharma, and specialty pharma sectors. Tess works on both public and private investments and serves on several company boards. She previously held roles as a Senior Business Analyst at Cambridge Associates and a Systems Analyst at Wellington Management Company. Soumya has more than two decades of experience in structure-based drug design and molecular modeling both in the areas of small molecules and biologics across multiple target classes and indications. Brendan holds a MS in Accounting with a concentration in Taxation from Merrimack College and a BA in Economics from University of Massachusetts Amherst. By continuing, you accept the use of these cookies. GREENWICH Peter Crumbine, a mainstay of public service in Greenwich for decades whose level-headed, friendly and professional manner earned . He earned his MS in Bioinformatics from Boston University. Copyright 2023 Surperformance. Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. He was also the co-founder and President of Research and Development of Cydan, a rare disease accelerator. Within the last 20 years alone, PJ Hogan had a go with 2003's Peter Pan (a major, almost $100m-losing flop), Joe Wright tried again in 2015 with the more radical Pan (another massive failure . Sophie led the cell therapy program, working with teams across the Trust to build capabilities to deliver industry and academically sponsored complex cell therapy trials for solid tumor cancer patients. Peter Balogh is an Analyst on the Investment Team at RA Capital Management. Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office. Michael Gillespie is an Analyst on the Venture Team at RA Capital Management. Robert also led the Sequencing Operations and Technology Development groups at the Broad for over 12 years, implementing industrial process control methods, developing multiple generations of high-throughput DNA sequencing technologies, and establishing an agile learning culture in the organization. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School. Tim received his A.B. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP, where he was responsible for accounting and valuation for the credit fund business, as well as the management company (US and Europe) and associated functions. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. He is a co-author on over 140 publications and is a co-inventor on 40 issued U.S. patents. Kathryns primary responsibility at RA is to invest in companies developing solutions that address climate change and environmental sustainability. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College. Emilys primary responsibility at RA Capital isdesigning and overseeing the brand management for RA Capital's internal and external communications as well assisting with the brand identity forportfolio companiesfounded through RA Capital's incubator, RA Ventures. Prior to this role, Anurag was at Orbimed Advisors where he served as Vice President, Structured Growth Capital and Royalty Opportunities. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in . David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. Prior to MPM, Sarah was the General Counsel for Charles River Ventures and before that, at Palomar Medical Technologies. Harveys primary responsibility is to oversee all accounting related activities for the firm. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics from the companys inception in 2017 until its acquisition by Eli Lilly in 2021. While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He worked previously as an Associate Managing Editor at EBSCO Health, and as a Medical Writer at IC Axon and Publicis Life Brands International.

Custom Mylar Bags Downtown Los Angeles, New Construction Homes In Nc Under $200k, Vibiana Los Angeles Wedding, Glenview Luxury Imports Staff, Osceola, Wi Airport Hangar, Articles P